Optimizing Clinically Actionable Biomarker Detection in Advanced Cancers by Next Generation Sequencing (NGS) Panel and Specimen Type
Understand how specimen type and NGS panel selection influence actionable biomarker detection.
This abstract evaluates matched cancer tissue and circulating tumor DNA (ctDNA) specimens from patients with advanced solid tumors to compare biomarker detection across different next-generation sequencing (NGS) strategies. The findings demonstrate how tissue and ctDNA provide complementary genomic insights that can support more informed precision oncology decision-making.